Board of Directors
Peter Høngaard Andersen
Chairman of the Board, Scandion Oncology and member of board of directors since June 2019.
Holds a degree in Chemistry, Biochemistry and medicine.
Extensive drug discovery and development experience from Novo Nordisk and Lundbeck latest as EVP and Head of Research and corporate patents.
Founder of Innovation Fund Denmark and Managing Director until May 2019 and chairing Innovative Medicines Initiative (IMI) from 2009 – 2014.
Co-founder of e.g. Acadia Pharmaceuticals, Zealand Pharma, Glycom, Epitherapeutics, Prexton Therapeutics.
Independence: Independent in relation to both the Company and executive management as well as larger shareholders.
Scandion Oncology shares and warrants
53.065 shares and 80.377 warrants
Jørgen Bardenfleth
Vice-Chairman of the Board, Scandion Oncology and member of board of directors since 2018.
Chairman of the Board in Lyngsoe Systems, Dubex, Symbion and Impero.
Boardmember in Bizbrains, Minerva, Accelerace, BLOXHUB (vice chair), et al.
Jørgen holds a Master of Science degree in Engineering from the Technical University of Denmark (DTU, 1980) and a Master of Business Administration degree from the University of California at Los Angeles (UCLA, 1989).
Independence: Independent in relation to both the Company and executive management as well as larger shareholders.
Scandion Oncology shares and warrants
410.629 shares and 53.585 warrants (Partly owned via Lioneagle ApS)
Carl Borrebäck
Member of the board of directors since 2018.
D.Sc, PhD.
Professor Lund University.
Co-founder of Immnovia AB, Senzagen AB, BioInvent International AB, Alligator BioScience AB.
Independence: Independent in relation to both the Company and executive management as well as larger shareholders.
Scandion Oncology shares and warrants
112.165 shares and 26.792 warrants (Partly owned via CB Ocean Capital AB)
Christian Vinding Thomsen
Member of the board of directors since 2017.
Partner, Bech-Bruun Law Firm.
Life Science specialist (M&A and regulatory).
Professional board member.
Christian holds a law degree (Cand.jur.) from the University of Copenhagen’s Faculty of Law.
Independence: Independent in relation to both the Company and executive management as well as larger shareholders.
Scandion Oncology shares and warrants
26.792 warrants
Thomas Feldthus
Member of the board of directors since 2018.
CEO of Fertilizer Invest ApS (M.Sc., MBA).
Previously, vVD, CFO and co-founder of Saniona and also CFO and co-founder of Symphogen A/S.
Independence: Independent in relation to both the Company and executive management as well as larger shareholders.
Scandion Oncology shares and warrants
18.182 shares and 26.792 warrants
Bo Rode Hansen
President & Chief Executive Officer
Member of the board of directors since May 2020
MSc, Ph.D., MBA
Previously: President and CEO of Genevant Sciences Inc.; Global Head of Roche RNA Therapeutics & General Manager of Roche Innovation Center Copenhagen; Executive, VP & Head of Drug Discovery & Alliance at Santaris (acquired by Roche).
Independence: Not independent in relation to the Company and executive management but independent in relation to larger shareholders.
Scandion Oncology shares and warrants
25.173 shares and 1.071.688 warrants
Annie Rasmussen
Employee elected. Member of the board of directors since 2020.
RN, Master of Public Health
Extensive Oncology Clinical Research & Operational experience from Oncology Clinics & Research Units, Smithkline Beecham and Biotech Companies since 1982. Former President of the Danish Oncology Nursing Society, Previous Co-founder & CCO of Topotarget A/S & EVP Clinical Operation Oncology Venture A/S. Founder of HealthCreationDK and CancerGuidesDK. Board Member of North Star Group A/S. CCO & Member of the Management Team in Scandion Oncology A/S.
Independence: Not independent in relation to the Company and executive management but independent in relation to larger shareholders.
Scandion Oncology shares and warrants
Please see under Management
